Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Drug ineffective08.06.01.0060.018996%Not Available
Drug interaction08.06.03.0010.006249%Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.001875%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphonia17.02.08.004; 22.12.03.006; 19.19.03.002--
Dyspnoea02.11.05.003; 22.02.01.0040.003749%
Dysuria20.02.02.002--
Ear pain04.03.01.003--
Ectropion23.07.05.001; 06.06.04.001--Not Available
Eczema23.03.04.006--
Embolism venous24.01.01.003--Not Available
Eosinophil count increased13.01.06.004--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.0010.004374%Not Available
Erythrodermic psoriasis23.03.14.007; 10.02.01.0740.001875%Not Available
Exostosis15.02.04.005--
Eye disorder06.08.03.001--Not Available
Eye haemorrhage12.02.02.012; 24.07.05.002; 06.07.02.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid ptosis06.05.01.002; 17.17.02.004--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene